GlaxoSmithKline (GSK) has filed two lawsuits against Moderna, alleging that Moderna infringes GSK’s patent rights in its mRNA coronavirus disease (mRNA) and respiratory syncytial virus (RSV) vaccines. woke up.
In a lawsuit filed Oct. 15 in U.S. District Court for the District of Delaware, GSK alleges that the technology used in Moderna’s SpikeVax COVID-19 vaccine and mResvia RSV vaccine to transport mRNA into the body. claimed to be infringing on GSK’s patent rights, and that the “patent has been obtained.” These inventions provide the foundation for Moderna’s mRNA vaccine portfolio. ”
In court documents, GSK lists seven lipid mRNA vaccine formulation technology patents that it claims Moderna infringed. The company said its patented mRNA technology was developed by a team led by Christian Mandl since 2008.
“Moderna acquired technical know-how regarding GSK Biologicals’ mRNA vaccine platform technology by hiring several former Novartis and GSK employees with first-hand knowledge of the Mandl team’s innovations,” GSK said in its complaint. It is written as follows. The company also claimed in its filing that Moderna cited the Mandl team’s patent applications in patent applications from 2013 onwards.
GSK did not disclose the amount it is seeking in damages, but it does seek “reasonable royalty recovery” and “all damages sufficient to compensate Moderna for its infringement,” as well as attorney’s fees and enforcement. Continuing license fees, and, according to court documents, “any other further relief at law or equity that this court deems just and appropriate.”
